The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Tumor necrosis factor antagonist therapy and lymphoma development: Twenty‐six cases reported to the Food and Drug Administration
Abstract
Objective: Etanercept and infliximab are tumor necrosis factor (TNF) antagonists that have been recently approved for the treatment of rheumatoid arthritis (RA) and Crohn's disease (CD). This study was undertaken to investigate the occurrence of lymphoproliferative disorders in patients treated with these agents. Methods: Relevant data in the MedWatch postmarket adverse event surveillance system run by the US Food and Drug Administration were reviewed. Results: We identified 26 cases of lymphoproliferative disorders following treatment with etanercept (18 cases) or infliximab (8 cases). The majority of cases (81%) were non‐Hodgkin's lymphomas. The interval between initiation of therapy with etanercept or infliximab and the development of lymphoma was very short (median 8 weeks). In 2 instances (1 infliximab, 1 etanercept), lymphoma regression was observed following discontinuation of anti‐TNF treatment, in the absence of specific cytotoxic therapy directed toward the lymphoma. Conclusion: Although data from a case series such as this cannot establish a clear causal relationship between exposure to these medications and the risk of lymphoproliferative disease, the known predisposition of patients with RA and CD to lymphoma, the known excess of lymphoma in other immunosuppressed populations, and the known immunosuppressive effects of the anti‐TNF drugs provide a biologic basis for concern and justification for the initiation of additional epidemiologic studies to formally evaluate this possible association.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SEER Cancer Statistics Review, 1975-2003
Ries, L. A. G., Harkins, D., Krapcho, M. F., Mariotto, A. B., Miller, B., Feuer, E. J., Clegg, L. X., Eisner, M. P., Horner, M., Howlader, N., et al. (2006) · Digital Archive @ GSU · Cited by 11,781
Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
Keane, J., Gershon, S., Wise, R. P., Mirabile-Levens, E., Kasznica, J., Schwieterman, W. D., Siegel, J. N., & Braun, M. M. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011110 · Cited by 3,710
Self-citationTargan, S. R., Hanauer, S. B., van Deventer, S. J. H., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F., & Rutgeerts, P. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371502 · Cited by 3,135
Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis
Lipsky, P. E., van der Heijde, D. M. F. M., St. Clair, E. W., Furst, D. E., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Weisman, M., Emery, P., Feldmann, M., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011303432202 · Cited by 2,996
Maini, R., St Clair, E. W., Breedveld, F., Furst, D., Kalden, J., Weisman, M., Smolen, J., Emery, P., Harriman, G., Feldmann, M., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)05246-0 · Cited by 2,345
A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis
Bathon, J. M., Martin, R. W., Fleischmann, R. M., Tesser, J. R., Schiff, M. H., Keystone, E. C., Genovese, M. C., Wasko, M. C., Moreland, L. W., Weaver, A. L., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011303432201 · Cited by 1,730
Etanercept in Children with Polyarticular Juvenile Rheumatoid Arthritis
Lovell, D. J., Giannini, E. H., Reiff, A., Cawkwell, G. D., Silverman, E. D., Nocton, J. J., Stein, L. D., Gedalia, A., Ilowite, N. T., Wallace, C. A., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003163421103 · Cited by 1,246
Starzl, T. E., Porter, K. A., Iwatsuki, S., Rosenthal, J. T., Shaw, B. W., Atchison, R. W., Nalesnik, M., Ho, M., Griffith, B. P., Hakala, T. R., et al. (1984) · The Lancet · doi:10.1016/s0140-6736(84)90994-2 · Cited by 1,234
Cancer risk in patients with inflammatory bowel disease: A population-based study
Bernstein, C. N., Blanchard, J. F., Kliewer, E., & Wajda, A. (2001) · Cancer · doi:10.1002/1097-0142(20010215)91:4<854::aid-cncr1073>3.0.co;2-z · Cited by 1,165
INFLIXIMAB AND METHOTREXATE IN THE TREATMENT OF RHEUMATOID ARTHRITIS
Ipsky, P. E. E. L., Illiam, E. W., Urst, D. A. E. F., Reedveld, C. B., Oachim, J., Alden, R. K., Osef, J., Molen, S. S., Eisman, M. I. W., Mery, P. A. E., et al. (2000) · Cited by 1,155
Rutgeerts, P., D'Haens, G., Targan, S., Vasiliauskas, E., Hanauer, S. B., Present, D. H., Mayer, L., Van Hogezand, R. A., Braakman, T., DeWoody, K. L., et al. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70332-x · Cited by 1,080
Nalesnik, M. A., Jaffe, R., Starzl, T. E., et al. (1988) · PubMed · Cited by 700
Incidence of Cancer Among Patients With Rheumatoid Arthritis
Gridley, G., McLaughlin, J. K., Ekbom, A., Klareskog, L., Adami, H.-O., Hacker, D. G., Hoover, R., & Fraumeni, J. F. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.4.307 · Cited by 581
Saxne, T., Palladino, M. A., Heinegãrd, D., Talal, N., & Wollheim, F. A. (1988) · Arthritis & Rheumatism · doi:10.1002/art.1780310816 · Cited by 566
Sandborn, W. J., & Hanauer, S. B. (1999) · Inflammatory Bowel Diseases · doi:10.1097/00054725-199905000-00008 · Cited by 454
Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis
Isomäki, H. A., Hakulinen, T., & Joutsenlahti, U. (1978) · Journal of Chronic Diseases · doi:10.1016/0021-9681(78)90071-1 · Cited by 433
Baecklund, E., Ekbom, A., Sparén, P., Feltelius, N., & Klareskog, L. (1998) · BMJ · doi:10.1136/bmj.317.7152.180 · Cited by 394
Rheumatoid arthritis and cancer risk
Mellemkjær, L., Linet, M. S., Gridley, G., Frisch, M., Møller, H., & Olsen, J. H. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(96)00210-9 · Cited by 383
Salloum, E., Cooper, D. L., Howe, G., Lacy, J., Tallini, G., Crouch, J., Schultz, M., & Murren, J. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.6.1943 · Cited by 380
Risk of malignancy among patients with rheumatic conditions
Thomas, E., Brewster, D. H., Black, R. J., & Macfarlane, G. J. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20001101)88:3<497::aid-ijc27>3.0.co;2-j · Cited by 332
Azathioprine for maintenance of remission in Crohn's disease: Benefits outweigh the risk of lymphoma
Lewis, J. D., Schwartz, J. S., & Lichtenstein, G. R. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70353-2 · Cited by 242
Infliximab: A Review of its Use in the Management of Rheumatoid Arthritis
Markham, A., & Lamb, H. M. (2000) · Drugs · doi:10.2165/00003495-200059060-00010 · Cited by 227
Adverse-Drug-Reaction Monitoring
Faich, G. A. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606123142427 · Cited by 223
Gross, T., Steinbuch, M., DeFor, T., Shapiro, R., McGlave, P., Ramsay, N., Wagner, J., & Filipovich, A. (1999) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1701554 · Cited by 215
The relationship between infliximab treatment and lymphoma in Crohn's disease
Bickston, S. J., Lichtenstein, G. R., Arseneau, K. O., Cohen, R. B., & Cominelli, F. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70294-5 · Cited by 203
Overview of the Epidemiology of Immunodeficiency-Associated Cancers
Beral, V., & Newton, R. (1998) · JNCI Monographs · doi:10.1093/oxfordjournals.jncimonographs.a024164 · Cited by 131
Neoplasms of the immune system in rheumatoid arthritis
Symmons, D. P. M. (1985) · The American Journal of Medicine · doi:10.1016/0002-9343(85)90241-4 · Cited by 110
Sandborn, W. J., & Hanauer, S. B. (2007) · Inflammatory Bowel Diseases · doi:10.1002/ibd.3780050209 · Cited by 102
Lymphoma in Patients with Rheumatoid Arthritis
Georgescu, L., & Paget, S. A. (1999) · Drug Safety · doi:10.2165/00002018-199920060-00002 · Cited by 83
A Review of Epstein-Barr Virus Infection in Patients with Immunodeficiency Disorders
Okano, M., & Gross, T. G. (2000) · The American Journal of the Medical Sciences · doi:10.1016/s0002-9629(15)40780-3 · Cited by 53
REES, L. H., Thomas, A. J., & Amlot, P. L. (1998) · The Lancet · doi:10.1016/s0140-6736(05)60684-8 · Cited by 44
Cited by
Infliximab Maintenance Therapy for Fistulizing Crohn's Disease
Sands, B. E., Anderson, F. H., Bernstein, C. N., Chey, W. Y., Feagan, B. G., Fedorak, R. N., Kamm, M. A., Korzenik, J. R., Lashner, B. A., Onken, J. E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030815 · Cited by 2,226
Breedveld, F. C., Weisman, M. H., Kavanaugh, A. F., Cohen, S. B., Pavelka, K., Vollenhoven, R. V., Sharp, J., Perez, J. L., & Spencer‐Green, G. T. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21519 · Cited by 1,785
Guidelines of care for the management of psoriasis and psoriatic arthritis
Menter, A., Gottlieb, A., Feldman, S. R., Van Voorhees, A. S., Leonardi, C. L., Gordon, K. B., Lebwohl, M., Koo, J. Y. M., Elmets, C. A., Korman, N. J., et al. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.02.039 · Cited by 1,222
Colombel, J.-F., Loftus, E. V., Tremaine, W. J., Egan, L. J., Harmsen, W. S., Schleck, C. D., Zinsmeister, A. R., & Sandborn, W. J. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.10.047 · Cited by 899
Baecklund, E., Iliadou, A., Askling, J., Ekbom, A., Backlin, C., Granath, F., Catrina, A. I., Rosenquist, R., Feltelius, N., Sundström, C., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21675 · Cited by 890
Metadata
- Authors
- Brown, S. L., Greene, M. H., Gershon, S. K., Edwards, E. T., & Braun, M. M.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2002-12
- Volume
- 46
- Issue
- 12
- Pages
- 3151-3158
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2127281820
- Cited by
- 655
- References
- 31
- FWCI
- 36.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.